APR 27, 2017 02:36 PM PDT

Technique Prevents Graft-Versus-Host Disease

WRITTEN BY: Xuan Pham

Bone marrow transplants are often considered to be the last resort treatment, because the procedure could have the nearly same chance of saving a patient as it does harming the patient. But now, scientists at the City of Hope say they have found a way to make the procedure safer for patients.

For patients with leukemia or lymphoma, a stem cell or bone marrow transplant is considered the only curative therapy. The procedure replaces a patient’s diseased blood stem cells with healthy ones from a matched donor. But in some cases, the donor’s cells can attack the recipient’s health tissues, and can cause tremendous multiple organ complications. This attack is known as graft-versus-host disease (GVHD).

"Currently, immunosuppressive drugs have been used to prevent GVHD, but immune-suppressants also subdue the anti-cancer effects of the donor T cells, potentially resulting in cancer relapse, in addition to other side effects such as an increased risk of infection," said Defu Zeng, who led the international collaboration at the City of Hope. "Therefore, prevention of GVHD while preserving anti-cancer effects remains the 'holy grail' of allogenic HCT [hematopoietic cell transplantation]." Of note, allogenic HTC refers to using stem cells derived from a donor.

The team report that one way to prevent GVHD is to temporarily deplete a specific type of of donor T cells, called CD4+, following the infusion of stem cells. In the absence of low CD4+ cells, another type of T cells, called CD8+, seems to be more focused on destroying tumor cells rather than the healthy cells. This has the effect of boosting graft-versus-leukemia, while preventing graft-versus-host disease.

"If successfully translated into clinical application, this regimen may represent one of the novel approaches that allow strong GVL effects without causing GVHD," said Zeng. "This kind of regimen has the potential to promote wide-spread application of allogenic HCT as a curative therapy for hematological malignancies."

So far the study has been limited to mouse models. Next, Zeng and colleagues plan to apply this method in human clinical trials.

Additional sources: City of Hope

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
APR 14, 2018
Immunology
APR 14, 2018
A Vaccine for When Cancer Forms from Human Retroviruses
A vaccine to prevent leukemia and other diseases of the immune system caused by a specific viral infection is now a very real idea. A new study from Kyoto ...
APR 27, 2018
Clinical & Molecular DX
APR 27, 2018
Stomach Pain Is A Warning Sign for Meningitis
Simply looking out for the classic warning signs of a meningococcal infection may cause some cases to go unnoticed - at first. A new study from the Institu...
MAY 23, 2018
Clinical & Molecular DX
MAY 23, 2018
Rapidly Screening Genes in 'Living Test Tubes'
Diagnosing rare disorders is often extremely challenging. Now scientists have developed a new tool for that purpose....
JUN 12, 2018
Immunology
JUN 12, 2018
Auto-antibody Detection for Rheumatoid Arthritis Patients
No case of rheumatoid arthritis (RA), an autoimmune disease, is the same. Now, researchers want RA diagnostic approaches to match its pathological diversit...
AUG 06, 2018
Infographics
AUG 06, 2018
What's in your blood?
Even though we only tend to focus on four key blood types, there are actually hundreds of iterations of different proteins and other components that make u...
OCT 17, 2018
Cell & Molecular Biology
OCT 17, 2018
Saving Patients From Unnecessary Chemotherapy with a Blood Test
Often, cancer patients get chemotherapy after surgery to ensure that their cancer will not come back; for many it's not needed....
Loading Comments...